Immuno-oncology Pliant's integrin inhibitor PLN-101095 cleared to enter clinic for solid tumors Feb. 3, 2023 Pliant Therapeutics Inc. has received FDA clearance of its IND application for PLN-101095, an oral, small-molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.Read More
